Outcome of Childhood Transverse Myelitis and Association with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210521006

Enrollment

Registered

2021-05-21

Start date

2021-05-24

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

transverse myelitis children, transverse myelitis, prognostic factor, anti-MOG, neuromyelitis optica, NMO, NMOSD

Interventions

All patients aged under 15 years with confirmed diagnosis of acute transverse myelitis

Other

acute transverse myelitis

Eligibility

Sex/Gender

All

Age

1 Months to 15 Years

Inclusion criteria

Inclusion criteria: patients aged under 15 years with confirmed diagnosis of acute transverse myelitis and follow-up time over a period of 6 months between January 2000 to August 2021 in Ramathibodi Hospital

Exclusion criteria

Exclusion criteria: histories of post spinal radiation, spinal vascular malformation, thrombosis of spinal artery, infectious myelitis

Design outcomes

Primary

Measure	Time frame
MOG Ab 12 month blood test,clinical good outcome 12 month motor power	—

Secondary

Measure	Time frame
ambulation 12 month questionaire	—

Countries

Thailand

Contacts

Public ContactLalida Wisedjinda

Mahidol University

lalidawised@gmail.com0886002244

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026